Earnings Per Share ("EPS") (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2025		Sep. 30, 2024	Sep. 30, 2025		Sep. 30, 2024
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net income (loss) available for common stockholders		$ 51.3		$ 34.6	$ 50.2		$ 184.2
Dividends paid					157.7		156.4
Net income (loss) available for common stockholders	[1]	49.1		32.4	43.6		177.6
Net income (Ioss) available for common stockholders		$ 49.1	[1]	$ 34.6	$ 43.6	[1]	$ 184.2	[2]
Weighted average number of shares for basic EPS (shares)		167.2		162.0	166.9		161.8
Dilutive potential shares from grants of RSUs and PRSUs (shares)		1.3	[3]	1.2	1.2	[3]	0.8
Dilutive potential shares from common stock issuable upon conversion of the Series A Preferred Stock (shares)		7.8	[4]	0.0	0.0	[4]	7.8
Weighted average number of shares for diluted EPS (shares)	[3],[4]	176.3		163.2	168.1		170.4
Series A Preferred Stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Dividends paid		$ 2.2		$ 2.2	$ 6.6		$ 6.6
Stock compensation plan
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from EPS calculation (shares)		0.1			0.1		1.0
Series A Preferred Stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from EPS calculation (shares)				7.8	7.8

[1] For the nine months ended September 30, 2025, and the three months ended September 30, 2024, Net income available for common stockholders for the calculation of both basic and diluted EPS. For the three months ended September 30, 2025, and the nine months ended September 30, 2024, Net income available for common stockholders for the calculation of basic EPS.

[2] For the three months ended September 30, 2025, and the nine months ended September 30, 2024, Net income available for common stockholders for the calculation of diluted EPS.

[3] The potential impact of 0.1 million granted RSUs and PRSUs in the three months ended September 30, 2025, 0.1 million granted RSUs and PRSUs in the nine months ended September 30, 2025, and 1.0 million granted RSUs and PRSUs in the nine months ended September 30, 2024, were antidilutive.

[4] The potential impact of 7.8 million shares of our common stock issuable upon conversion of the Series A Preferred Stock in the three months ended September 30, 2024 and 7.8 million shares of our common stock issuable upon conversion of the Series A Preferred Stock in the nine months ended September 30, 2025, were antidilutive.